TWC
DNTH icon

TD Waterhouse Canada’s Dianthus Therapeutics DNTH Stock Holding History

TD Waterhouse Canada’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-203
Closed -$5.66K – 1995
2024
Q3 		$5.66K Buy
+203
New +$5.65K ﹤0.01% 1466

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TD Waterhouse Canada's DNTH Position: Q4 2024 in Review

TD Waterhouse Canada sold out of Dianthus Therapeutics (DNTH) in Q4 2024, closing a stake of 203 shares — an estimated $5.66K sold.

TD Waterhouse Canada first reported a position in DNTH in Q3 2024 and held it in 1 quarter. The position peaked at $5.66K in Q3 2024. 95 funds tracked by Wall St. Rank hold DNTH as of Q4 2024.

  • TD Waterhouse Canada reported no remaining Dianthus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • TD Waterhouse Canada sold 203 Dianthus Therapeutics shares in Q4 2024, an estimated $5.66K.
  • TD Waterhouse Canada first reported a position in Dianthus Therapeutics in Q3 2024 and held it in 1 quarter.
  • TD Waterhouse Canada's Dianthus Therapeutics position peaked at $5.66K in Q3 2024.
  • 95 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2024.

Based on TD Waterhouse Canada's 13F filing for Q4 2024, filed 13 Feb 2025.